HOME >> MEDICINE >> NEWS
Heart-stopping drugs

A NEW way of stopping the heart during bypass operations could reduce damage to the heart and improve patients' chances of a full recovery.

More than a million people a year have open-heart surgery to unblockor bypass clogged arteries, or repair damaged valves. The heart is usually stopped for about one hour while they are under the knife because it is impossible to operate on a moving target. But the standard method of achieving this- flooding the heart with potassium ions- can cause permanent damage.

Now Geoffrey Dobson and Michael Jones of James Cook University in Townsville, Australia, have developed an alternative. It has only been tested on animals so far, but experts say the results, due to appear in the Journal of Thoracic and Cardiovascular Surgery, look promising. "By keeping potassium levels normal they are preventing injuries to the muscle cells and to the vessels that carry blood to the heart," says Peter Macdonald, a cardiologist at St Vincent's Hospital in Sydney.

In resting muscle cells, the distribution of ions across the cell membrane generates an electric potential. The waves of electrical activity that sweep across the heart, telling muscle cells to contract, are generated when channels in the membrane open, allowing ions to flow across the membrane and depolarise the cells. Flooding the heart with potassium ions freezes its cells in this depolarised state.

Dobson and Jones instead freeze the heart in the resting state using two drugs: adenosine, which opens some of the channels that transport potassium ions in and out of the cell, and lignocaine (known as lidocainein the US), which blocks sodium ion channels.

"There are two ways to stop a heart cell. Let it run out of gas- that's the potassium infusion-or to not even turn it on. That's what Dobson has done," says Jakob Vinten-Johansen, a cardiovascular physiologist at Emory University in Atlanta, Georgia, who now collaborates with Dobson.

Whe
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
17-Sep-2003


Page: 1 2 3

Related medicine news :

1. UW research shows risk factors for relapse among health care professionals who abuse drugs
2. New studies show mixed results on epilepsy drugs and birth defects
3. Newly discovered pathway might help in design of cancer drugs
4. Study examines consequences of Thailands war on drugs
5. Computational tool predicts how drugs work in cells, advancing efforts to design better medicines
6. Three anti-platelet drugs used in combination are safe
7. HIV patients may be at risk of heart problems when taking protease inhibitor drugs
8. Clot-busting drugs may help detect potentially deadly leg clots
9. Herb used to treat diabetes works like modern-day prescription drugs, study suggests
10. Penn study shows how next-generation diabetic drugs could work more selectively
11. Study shows drugs such as Vioxx and Celebrex were widely over-used long before recent problems

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Heart stopping drugs

(Date:7/30/2015)... ... 2015 , ... In an effort to provide the twenty four hour continuous ... in his practice. , The decision will also allow him to spend more time ... transferring his in-patient admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... TikiLIVE, has worked to protect victims in San Diego, California’s Gaslamp Quarter Plaza ... used by Gaslamp Quarter Plaza actively monitor the area for any suspicious activity. ...
(Date:7/30/2015)... ... July 30, 2015 , ... " DevExpress ... takes a look at small, medium, and large businesses making an impact in ... the business review and shared with viewers how DevExpress has provided software development ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... Institute Scholar Program. In partnership with Patient Experience Institute, these offerings reinforce the ... on the front lines and throughout the experience movement, and provide information and ...
(Date:7/30/2015)... Beach, California (PRWEB) , ... July 30, 2015 ... ... and services, announced today that the latest issue of Inclusive™ magazine, its multimedia ... digital platforms. The digital edition of the new issue, Volume 6, Issue 2, ...
Breaking Medicine News(10 mins):Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
(Date:7/30/2015)... 30, 2015 Vermillion, Inc. (VRML), ... disease, announced today it will report its ... market close on Thursday, August 13, 2015, ... webcast at 4:30pm Eastern.Conference Call and Webcast:  ... Eastern/1:30pm Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... -- Big Cloud Analytics, Inc. (BCA), a leading provider ... working with Intel Corporation to showcase Internet of ... Healthcare Technology Alliance. The recently formed alliance is ... technology companies and academic institutions. Its purpose is ... in rapidly evolving and growing areas of health ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
Cached News: